American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update
Samson S, Vellanki P, Blonde L, Christofides E, Umpierrez G et al
On line 5 mayo 2023, Endocrine Practice
https://doi.org/10.1016/j.eprac.2023.02.001
Impacts of COVID-19 on Glycemia and Risk of Diabetic Ketoacidosis
Sharma A, Misra-Heberth A, Mariam A, Milinovich A, Onuzuruike, A et al
Diabetes 2023;72(5):627–637
https://doi.org/10.2337/db22-0264
Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes
Heller S, Battelino, Bailey T, Pieber T, Pieber T et al
doi.org/10.1111/dom.14987
Management of adults with diabetes on dialysis: Summary of recommendations of the Joint British Diabetes Societies guidelines 2022
Frankel A, Whaba M, Ashworth V, Bedi R, Berrington et al
https://doi.org/10.1111/dme.15027
Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL Around Spontaneous Exercise Sessions in Adults with Type 1 Diabetes: A Randomized Cross-Over Trial (ULTRAFLEXI-1 Study)
Moser O, Muller F, Aberer F, Aziz F; koizar H et al
Diabetes Technol Ther. 2023 Mar;25(3):161-168.
https://doi.org/10.1089/dia.2022.0422
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial.
Feig D, Sanchez J, Murphy K, Astalos E, Zinman B, Sinmons D et al.
Lancet Diabetes Endocrinol. 2023 Mar;11(3):191-202.
www.doi.org/10.1016/S2213-8587(23)00004-9
Comentarios recientes